Aulos Bioscience
Cambridge, US · Founded 2020 · Delaware corporation
Aulos develops immune-activating antibody therapeutics for cancer treatment, using artificial intelligence to design monoclonal antibodies that modulate interleukin-2 activity to enhance immune activation in immuno-oncology.
Founders & leadership
ME
Michael EhlersExecutive Officer, Director
RC
Rajesh ChopraDirector
JY
Joseph YanchikDirector
YO
Yanay OfranExecutive Officer, Director
YB
Yechezkel BarenholzDirector
MP
Micah PearlmanExecutive Officer
Reported raises · per SEC filings
Form D private placements▶$5MraisedAug 2023 · 1 investors · BiotechnologyRule 506(b)
Officers, directors & promoters on the filing
- Seth HarrisonDirector
- Rajesh ChopraDirector
- Anna BatarinaDirector
- Aron KnickerbockerExecutive Officer, Director
- James VasselliExecutive Officer
- Michael EhlersDirector
- Mace RothenbergDirector
- Yanay OfranDirector
- Leo J. RedmondExecutive Officer
- Offering amount
- $20M
- Amount sold
- $5M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$15MraisedNov 2020 · 1 investors · BiotechnologyRule 506(b)
Officers, directors & promoters on the filing
- Michael EhlersExecutive Officer, Director
- Rajesh ChopraDirector
- Joseph YanchikDirector
- Yanay OfranExecutive Officer, Director
- Yechezkel BarenholzDirector
- Micah PearlmanExecutive Officer
- Offering amount
- $40M
- Amount sold
- $15M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.